Back to Search
Start Over
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
- Source :
-
British Journal of Haematology . Jun2024, Vol. 204 Issue 6, p2227-2232. 6p. - Publication Year :
- 2024
-
Abstract
- Summary: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant‐eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment‐emergent adverse events. In summary, these findings suggest a benefit of D‐RVd front‐line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- *BLACK people
*DARATUMUMAB
*LENALIDOMIDE
*BORTEZOMIB
*HEALTH services accessibility
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 204
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 177903496
- Full Text :
- https://doi.org/10.1111/bjh.19386